The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease

Melissa J. Armstrong; Sarah Duff-Canning; David F. Tang-Wai; Susan Fox; Cindy Zadikoff; Nancy Kennedy; David Gill; Paul J. Eslinger; Mark Mapstone; Kelvin L. Chou; Carol Persad; Irene Litvan; Benjamin T. Mast; Connie Marras

doi:10.1016/j.parkreldis.2012.09.005

The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease

Melissa J. Armstrong, Sarah Duff-Canning, David F. Tang-Wai, Susan Fox, Cindy Zadikoff, Nancy Kennedy, David Gill, Paul J. Eslinger, Mark Mapstone, Kelvin L. Chou, Carol Persad, Irene Litvan, Benjamin T. Mast, Connie Marras

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	463-465
Number of pages	3
Journal	Parkinsonism and Related Disorders
Volume	19
Issue number	4
DOIs	https://doi.org/10.1016/j.parkreldis.2012.09.005
State	Published - Apr 2013

All Science Journal Classification (ASJC) codes

Neurology
Geriatrics and Gerontology
Clinical Neurology

Access to Document

10.1016/j.parkreldis.2012.09.005

Cite this

Armstrong, M. J., Duff-Canning, S., Tang-Wai, D. F., Fox, S., Zadikoff, C., Kennedy, N., Gill, D., Eslinger, P. J., Mapstone, M., Chou, K. L., Persad, C., Litvan, I., Mast, B. T., & Marras, C. (2013). The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease. Parkinsonism and Related Disorders, 19(4), 463-465. https://doi.org/10.1016/j.parkreldis.2012.09.005

Armstrong, Melissa J. ; Duff-Canning, Sarah ; Tang-Wai, David F. ; Fox, Susan ; Zadikoff, Cindy ; Kennedy, Nancy ; Gill, David ; Eslinger, Paul J. ; Mapstone, Mark ; Chou, Kelvin L. ; Persad, Carol ; Litvan, Irene ; Mast, Benjamin T. ; Marras, Connie. / The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease. In: Parkinsonism and Related Disorders. 2013 ; Vol. 19, No. 4. pp. 463-465.

@article{99e1f1f2b5664353b16895f89266bb56,

title = "The meaning of a {"}hippo{"} response on the Montreal Cognitive Assessment in Parkinson's disease",

author = "Armstrong, {Melissa J.} and Sarah Duff-Canning and Tang-Wai, {David F.} and Susan Fox and Cindy Zadikoff and Nancy Kennedy and David Gill and Eslinger, {Paul J.} and Mark Mapstone and Chou, {Kelvin L.} and Carol Persad and Irene Litvan and Mast, {Benjamin T.} and Connie Marras",

note = "Funding Information: This study was supported by a grant from the Michael J. Fox Foundation . Melissa J. Armstrong: Support as an Edmond J. Safra fellow at Toronto Western Hospital while working on this project. Current research support from Abbott . Sarah Duff-Canning: Research support from Michael J Fox Foundation, National Parkinson Foundation , and Canadian Institutes of Health Research . Susan Fox: Research support from the Parkinson Society Canada, Michael J. Fox Foundation, and NIH. Consultancy from Teva, Novartis, Santhera, Merz, Merck Serono. Cindy Zadikoff: Research support from Parkinson Alliance . Consultancy and honoraria from Teva, GSK, Merz, Allergan, Ipsen, and Abbott. Paul J. Eslinger: Research support from National Institute of Health ( NS060722 , ES019672 , AG027771 ) and the Pennsylvania Department of Health . Mark Mapstone: Research support from the National Institute of Health, Michael J. Fox Foundation, Neurologix, Inc. , and Advanced Neuromodulation System, Inc . Honoraria from the Michael J. Fox Foundation. Kelvin L. Chou: Research support from the National Institute of Health ( NS44504-08 ) and participates as a site-PI in clinical trials sponsored by the HSG (PHAROS, 2CARE, and CREST-HD). Royalties from UpToDate. Speaking honoraria from Allergan. Consulting honoraria for Medtronic and Merz Pharmaceuticals. Carol Persad: Research support from National Institute of Health ( P01 NS015655-26A1 , MCASTL RFP2010-04 ). Irene Litvan: Research support from National Institute of Health ( R01 PAS-03-092 NIA), National Parkinson Foundation, Parkinson Support Center of Kentuckiana, CurePSP, Noscira, Allon Therapeutics, and Parkinson Study Group. Consultant for Teva, Novartis, Santhera, Merz, Merck Serono, and Bristol-Myers Squibb. Connie Marras: Research support from the Canadian Institutes of Health Research, Michael J. Fox Foundation, National Parkinson Foundation, Merck Serono and Allon Therapeutics. David F. Tang-Wai, Nancy Kennedy, David Gill, and Benjamin T. Mast report no disclosures. Funding Information: This study was supported by a grant from the Michael J. Fox Foundation. We would like to thank Fred Marshall, MD (Department of Neurology, University of Rochester), who also contributed to data collection and Brandon Rothberg, HBA (Toronto Western Hospital Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease) for assistance with the study database. Melissa J. Armstrong received support as an Edmond J. Safra fellow at Toronto Western Hospital while working on this project.",

year = "2013",

month = apr,

doi = "10.1016/j.parkreldis.2012.09.005",

language = "English (US)",

volume = "19",

pages = "463--465",

journal = "Parkinsonism and Related Disorders",

issn = "1353-8020",

publisher = "Elsevier BV",

number = "4",

}

Armstrong, MJ, Duff-Canning, S, Tang-Wai, DF, Fox, S, Zadikoff, C, Kennedy, N, Gill, D, Eslinger, PJ, Mapstone, M, Chou, KL, Persad, C, Litvan, I, Mast, BT & Marras, C 2013, 'The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease', Parkinsonism and Related Disorders, vol. 19, no. 4, pp. 463-465. https://doi.org/10.1016/j.parkreldis.2012.09.005

The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease. / Armstrong, Melissa J.; Duff-Canning, Sarah; Tang-Wai, David F.; Fox, Susan; Zadikoff, Cindy; Kennedy, Nancy; Gill, David; Eslinger, Paul J.; Mapstone, Mark; Chou, Kelvin L.; Persad, Carol; Litvan, Irene; Mast, Benjamin T.; Marras, Connie.

In: Parkinsonism and Related Disorders, Vol. 19, No. 4, 04.2013, p. 463-465.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease

AU - Armstrong, Melissa J.

AU - Duff-Canning, Sarah

AU - Tang-Wai, David F.

AU - Fox, Susan

AU - Zadikoff, Cindy

AU - Kennedy, Nancy

AU - Gill, David

AU - Eslinger, Paul J.

AU - Mapstone, Mark

AU - Chou, Kelvin L.

AU - Persad, Carol

AU - Litvan, Irene

AU - Mast, Benjamin T.

AU - Marras, Connie

N1 - Funding Information: This study was supported by a grant from the Michael J. Fox Foundation . Melissa J. Armstrong: Support as an Edmond J. Safra fellow at Toronto Western Hospital while working on this project. Current research support from Abbott . Sarah Duff-Canning: Research support from Michael J Fox Foundation, National Parkinson Foundation , and Canadian Institutes of Health Research . Susan Fox: Research support from the Parkinson Society Canada, Michael J. Fox Foundation, and NIH. Consultancy from Teva, Novartis, Santhera, Merz, Merck Serono. Cindy Zadikoff: Research support from Parkinson Alliance . Consultancy and honoraria from Teva, GSK, Merz, Allergan, Ipsen, and Abbott. Paul J. Eslinger: Research support from National Institute of Health ( NS060722 , ES019672 , AG027771 ) and the Pennsylvania Department of Health . Mark Mapstone: Research support from the National Institute of Health, Michael J. Fox Foundation, Neurologix, Inc. , and Advanced Neuromodulation System, Inc . Honoraria from the Michael J. Fox Foundation. Kelvin L. Chou: Research support from the National Institute of Health ( NS44504-08 ) and participates as a site-PI in clinical trials sponsored by the HSG (PHAROS, 2CARE, and CREST-HD). Royalties from UpToDate. Speaking honoraria from Allergan. Consulting honoraria for Medtronic and Merz Pharmaceuticals. Carol Persad: Research support from National Institute of Health ( P01 NS015655-26A1 , MCASTL RFP2010-04 ). Irene Litvan: Research support from National Institute of Health ( R01 PAS-03-092 NIA), National Parkinson Foundation, Parkinson Support Center of Kentuckiana, CurePSP, Noscira, Allon Therapeutics, and Parkinson Study Group. Consultant for Teva, Novartis, Santhera, Merz, Merck Serono, and Bristol-Myers Squibb. Connie Marras: Research support from the Canadian Institutes of Health Research, Michael J. Fox Foundation, National Parkinson Foundation, Merck Serono and Allon Therapeutics. David F. Tang-Wai, Nancy Kennedy, David Gill, and Benjamin T. Mast report no disclosures. Funding Information: This study was supported by a grant from the Michael J. Fox Foundation. We would like to thank Fred Marshall, MD (Department of Neurology, University of Rochester), who also contributed to data collection and Brandon Rothberg, HBA (Toronto Western Hospital Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease) for assistance with the study database. Melissa J. Armstrong received support as an Edmond J. Safra fellow at Toronto Western Hospital while working on this project.

PY - 2013/4

Y1 - 2013/4

UR - http://www.scopus.com/inward/record.url?scp=84875248110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875248110&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2012.09.005

DO - 10.1016/j.parkreldis.2012.09.005

M3 - Letter

C2 - 23036511

AN - SCOPUS:84875248110

VL - 19

SP - 463

EP - 465

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 4

ER -